Denil Nanji Shekhat - 18 Jun 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MIRA	Nonqualified Stock Option (right to buy)	Award	$0	+50,000		$0.000000	41,666	18 Jun 2024	Common Stock	50,000	$0.7100	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The exercise price of the stock options issued to the Reporting Person is equal to the Nasdaq Official Closing Price of the Issuer's common stock on June 18, 2024, the date of the grant.
F2	The stock options were issued to the Reporting Person on June 18, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"), and in accordance with the terms of a consulting agreement dated June 18, 2024, by and between the Reporting Person and MIRA Pharmaceuticals, Inc. The stock options will vest in three equal tranches, with the first tranche vesting immediately on the grant date of June 18, 2024, the second tranche vesting on December 18, 2024, and the final tranche vesting on June 18, 2025.
F3	Represents (i) 25,000 stock options that were issued to the Reporting person on March 25, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $1.16 each and (ii) 16,666 stock options that were issued to the Reporting Person on June 18, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.71 each.